exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089278 RNA Name: hsa-miR-650 RNA Type: miRNA Chromosome: chr22 Starnd: + Coordinate: Start Site(bp): 22822791 End Site(bp): 22822811 External Links: hsa-miR-650

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand POM121C chr7 75416786 75486299 - ATXN2L chr16 28823035 28837237 + RNF220 chr1 44405194 44651724 + POLE3 chr9 113407235 113410675 - SFN chr1 26863149 26864456 + SH3GL1 chr19 4360370 4400547 - STOM chr9 121338987 121370304 - HNRNPUL1 chr19 41262496 41307787 + LMNA chr1 156082573 156140089 + SLC9A3R1 chr17 74748628 74769353 + HPCAL1 chr2 10302889 10427617 + TRAF7 chr16 2155698 2178129 + GBF1 chr10 102245532 102382899 + ZNF623 chr8 143636013 143656418 + USP22 chr17 20999596 21043760 - POLDIP3 chr22 42583721 42614962 - VHL chr3 10141008 10152220 + ABL1 chr9 130713016 130887675 + TSKU chr11 76782251 76798153 + TRAPPC10 chr21 44012309 44106552 + SLC29A1 chr6 44219553 44234142 + HIF1AN chr10 100529072 100559998 + NBL1 chr1 19596979 19658456 + AFAP1 chr4 7758714 7939926 - CBFA2T3 chr16 88874858 88977207 - AKT2 chr19 40230317 40285536 - RAB1B chr11 66268590 66277492 + PAK4 chr19 39125770 39182816 + DUSP8 chr11 1554051 1572271 - TESMIN chr11 68707440 68751520 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001168 chr20 47691321 47707559 + hsa_circ_0001146 chr20 34241449 34246936 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC068768.1 chr12 123262060 123262402 + AC118758.3 chr7 56809214 56848800 - AL049796.1 chr1 93847174 93848939 + AL355075.4 chr14 20343048 20343685 - DSCAM-AS1 chr21 40383083 40385358 + KCNQ1OT1 chr11 2608328 2699994 - LINC01772 chr1 16460948 16468481 + MIR155HG chr21 25561909 25575168 + MIR663AHG chr20 26167817 26251546 - NEAT1 chr11 65422774 65445540 + TUG1 chr22 30969245 30979395 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.